Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Y2k_fan who wrote (730)	5/6/1998 12:42:00 AM
From: Jeffrey L. Henken	Respond to of 2887

How about the OmniStent designs in R&D from American BioMed? I think they will be very competitive. Although this information is slightly dated it is still valid: The OmniStent&trade: Although angioplasty and atherectomy contributed greatly to less invasive treatment of atherosclerosis, it was not until 1994 that a third less invasive means of treatment was developed. This new treatment, consisting of simple, spring-like devices call stents, which when place in a treated vessel, greatly reduces the acute and chronic clinical failure rate of restenosis. Stents provide a foundation to support a weakened vessel. The most common design is the metal stent which is comprised of a tubular structure, normally having a pattern of slots which, when expanded, produce a tiny tubular grillwork that can hold a diseased vessel open, thereby providing a channel for blood flow to the hear or limbs. To further imbed the coiled stent into the subintimal layers of the arterial wall, higher inflation pressures that expand the compliant delivery balloon to larger diameters are used. Combining The Company's stents with its atherectomy products provides a solid foundation for The Company's introduction into the atherectomy and stent endovascular markets which is growing at the rate of 25 to 50% per year according to a Cowen & Co. report. The OmniStent™ has been successfully manufactured using a unique, patented proprietary process that makes a one piece, endless loop without welding, soldering or annealing. The Company also has a proprietary process in which it forms and shapes the stents prior to use. The Company is also looking at metals other than stainless steel (which it has previously used) and is designing its own delivery catheter which may use a variation of its Evert-O-Cath™. The Company has patented two distinct stent configurations, the coil stent and the bifurcated stent. The coil stent is a straight coil wound in helix which would be used in supporting a longitudinal section of vessel such as a major coronary vessel, (i.e., left anterior descending or right coronary artery or a major peripheral vessel such as the aortic iliac or femoral). The coil is formed from an endless loop of wire formed in a plurality of arcuate sections. The bifurcated OmniStent™ is a Y-shaped bifurcated stent designed for use in aortic bifurcation. However, small versions may be used at any branched blood vessel. The bifurcated version is also an endless stent overcoming the deficiencies of prior art in construction. However, it is unique in design as no other company has solved the dilemma of manufacturing and deploying a bifurcated stent. All rely on a series of single stents, placed in close proximity, and usually requiring an access from each artery (lateral and contralateral femoral). This is very distressful to the patient requiring a surgical prep, artery puncture and catheter sheath on each side of the groin. Potentially it is twice as difficult, dangerous and time consuming to both patient and doctor as the bifurcated OmniCath. In addition, the Company has patented a proprietary process of reproducing the stents using photoetching which significantly reduces cost and production error. Regards, Jeff